ResMed Inc.RMDNYSE
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
1.02%
↓ 67% below average
Average (39q)
3.12%
Historical baseline
Range
High:22.31%
Low:-8.01%
CAGR
-4.7%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 1.02% |
| Q2 2025 | 2.98% |
| Q1 2025 | 3.16% |
| Q4 2024 | 2.33% |
| Q3 2024 | -1.65% |
| Q2 2024 | 4.91% |
| Q1 2024 | 4.32% |
| Q4 2023 | -2.42% |
| Q3 2023 | -3.11% |
| Q2 2023 | 2.23% |
| Q1 2023 | 9.39% |
| Q4 2022 | 10.58% |
| Q3 2022 | -1.76% |
| Q2 2022 | -3.72% |
| Q1 2022 | 6.87% |
| Q4 2021 | 4.27% |
| Q3 2021 | 0.13% |
| Q2 2021 | 7.03% |
| Q1 2021 | 1.83% |
| Q4 2020 | 0.74% |
| Q3 2020 | 3.83% |
| Q2 2020 | 2.08% |
| Q1 2020 | 3.02% |
| Q4 2019 | 3.98% |
| Q3 2019 | -6.07% |
| Q2 2019 | 7.41% |
| Q1 2019 | 10.44% |
| Q4 2018 | 11.14% |
| Q3 2018 | -2.18% |
| Q2 2018 | 5.94% |
| Q1 2018 | -7.90% |
| Q4 2017 | 8.63% |
| Q3 2017 | 1.93% |
| Q2 2017 | 4.49% |
| Q1 2017 | -8.01% |
| Q4 2016 | 10.87% |
| Q3 2016 | 0.19% |
| Q2 2016 | 22.31% |
| Q1 2016 | -2.97% |
| Q4 2015 | 6.54% |